Literature DB >> 11083494

Local administration of transcription factor decoy oligonucleotides to nuclear factor-kappaB prevents carrageenin-induced inflammation in rat hind paw.

F D'Acquisto1, A Ialenti, A Ianaro, R Di Vaio, R Carnuccio.   

Abstract

The transcription factor nuclear factor-kappaB (NF-kappaB) plays a key role in the expression of several genes involved in the inflammatory process. In the present study we investigated in an acute model of inflammation, the carrageenin-induced hind paw edema, the anti-inflammatory effect of double stranded oligodeoxynucleotides (ODN) with consensus nuclear factor-kappaB (NF-kappaB) sequence as transcription factor decoys (TFD) to inhibit NF-kappaB binding to native DNA sites. Local administration of wild-type, but not mutant-ODN decoy, dose-dependently inhibited edema formation induced by carrageenin in rat paw. Molecular analysis performed on soft tissue obtained from inflamed paw demonstrated: (1) an inhibition of NF-kappaB DNA binding activity; (2) a decreased nuclear level of p50 and p65 NF-kappaB subunits; (3) an inhibition of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) protein expression, two inflammatory enzymes transcriptionally controlled by NF-kappaB. Furthermore, SN-50, a cell-permeable peptide capable of inhibiting the nuclear translocation of NF-kappaB complexes, exhibited a similar profile of activity of ODN decoy. Our results indicate for the first time that ODN decoy, acting as an in vivo competitor for the transcription factor's ability to bind to cognate recognition sequence, may represent a novel strategy to modulate acute inflammation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083494     DOI: 10.1038/sj.gt.3301295

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

1.  Nuclear factor-kappaB regulates inflammatory cell apoptosis and phagocytosis in rat carrageenin-sponge implant model.

Authors:  Maria Chiara Maiuri; Gianfranco Tajana; Teresa Iuvone; Daniela De Stefano; Guido Mele; Maria Teresa Ribecco; Maria Pia Cinelli; Maria Fiammetta Romano; Maria Caterina Turco; Rosa Carnuccio
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

Review 2.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

3.  Hydroxytyrosol, a phenolic compound from virgin olive oil, prevents macrophage activation.

Authors:  Maria Chiara Maiuri; Daniela De Stefano; Paola Di Meglio; Carlo Irace; Maria Savarese; Raffaele Sacchi; Maria Pia Cinelli; Rosa Carnuccio
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-16       Impact factor: 3.000

4.  Nuclear factor kappa B is activated in small intestinal mucosa of celiac patients.

Authors:  Maria Chiara Maiuri; Daniela De Stefano; Guido Mele; Simona Fecarotta; Luigi Greco; Riccardo Troncone; Rosa Carnuccio
Journal:  J Mol Med (Berl)       Date:  2003-05-13       Impact factor: 4.599

5.  Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis.

Authors:  Oscar López-Franco; Yusuke Suzuki; Guillermo Sanjuán; Julia Blanco; Purificación Hernández-Vargas; Yoshikage Yo; Jeffrey Kopp; Jesús Egido; Carmen Gómez-Guerrero
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

6.  AAV-mediated expression of NFAT decoy oligonucleotides protects from cardiac hypertrophy and heart failure.

Authors:  Anca Remes; Andreas H Wagner; Markus Hecker; Oliver J Müller; Nesrin Schmiedel; Markus Heckmann; Theresa Ruf; Lin Ding; Andreas Jungmann; Frauke Senger; Hugo A Katus; Nina D Ullrich; Norbert Frey
Journal:  Basic Res Cardiol       Date:  2021-06-04       Impact factor: 17.165

7.  The Anti-Inflammatory Activity of Toonaciliatin K against Adjuvant Arthritis.

Authors:  HaiXing Gou; Jie Ye; YiRu Wang; XiaoLi Xu; QiXing Shen; JingWei Xue; Jie Zhao; XinGang Lu
Journal:  Biomed Res Int       Date:  2017-10-17       Impact factor: 3.411

Review 8.  Cell-Type Targeted NF-kappaB Inhibition for the Treatment of Inflammatory Diseases.

Authors:  Bettina Sehnert; Harald Burkhardt; Stefan Dübel; Reinhard E Voll
Journal:  Cells       Date:  2020-07-06       Impact factor: 6.600

Review 9.  Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer.

Authors:  Sander W Tas; Margriet J B M Vervoordeldonk; Paul P Tak
Journal:  Curr Gene Ther       Date:  2009-06       Impact factor: 4.391

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.